Alisporivir

Summary

Alisporivir (CHEMBL1651956) is a phase-3 clinical-stage protein; indicated across 5 conditions including hepatitis c virus infection and chronic hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 5 conditions
• Clinical trials: 14
• Chemistry: 1216.6 Da · C63H113N11O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1651956
Name	Alisporivir
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	11513676
Molecular formula	C63H113N11O12
Molecular weight	1216.6
InChIKey	OLROWHGDTNFZBH-XEMWPYQTSA-N

SMILES: CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C

IUPAC name: (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

Also known as: Alisporivir, DEB 025, DEB-025, DEB025, DEBIO 025, DEBIO-025, DEBIO025, UNIL 025, UNIL-025, UNIL025, ALISPORIVIR, alisporivir

Patent coverage: 294 distinct patent families (822 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Peptidyl-prolyl cis-trans isomerase A, Peptidyl-prolyl cis-trans isomerase B, Peptidyl-prolyl cis-trans isomerase F, mitochondrial, ATP-dependent translocase ABCB1, Broad substrate specificity ATP-binding cassette transporter ABCG2, ATP-binding cassette sub-family C member 2, Bile salt export pump.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPIA	9.47	Ki	0.34	nM	CHEMBL_ACT_5294527
PPIB	9	Kd	1	nM	CHEMBL_ACT_15083131
PPIF	9	Kd	1	nM	CHEMBL_ACT_15083135
PPIA	8.66	Kd	2.2	nM	CHEMBL_ACT_15083117
PPIA	8.1	Kd	8	nM	CHEMBL_ACT_29162337
PPIA	7.96	Kd	11	nM	CHEMBL_ACT_12204721
ABCB11	6.96	IC50	110	nM	CHEMBL_ACT_15083160
SLCO1B1	6.75	IC50	180	nM	CHEMBL_ACT_15083154
SLCO1B3	6.66	IC50	220	nM	CHEMBL_ACT_15083156
ABCB1	6.23	IC50	590	nM	CHEMBL_ACT_15083164
SLCO1B1	6.1	IC50	800	nM	CHEMBL_ACT_15078593
ABCG2	5.6	IC50	2500	nM	CHEMBL_ACT_15083162

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
liver disorder	2	MONDO:0005154	EFO:0001421
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
chronic kidney disease	1	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	4
PHASE1	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01318694	PHASE3	COMPLETED	Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
NCT01446250	PHASE3	TERMINATED	Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
NCT01500772	PHASE3	TERMINATED	Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
NCT02753699	PHASE3	COMPLETED	Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
NCT00537407	PHASE2	COMPLETED	A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
NCT01183169	PHASE2	COMPLETED	Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
NCT01215643	PHASE2	COMPLETED	Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
NCT02094443	PHASE2	COMPLETED	Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
NCT04608214	PHASE2	COMPLETED	Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)
NCT01860326	PHASE1	COMPLETED	Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
NCT01975337	PHASE1	COMPLETED	Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
NCT02173574	PHASE1	COMPLETED	Two-way Interaction Between Alisporivir and EDP239
NCT00854802	Not specified	COMPLETED	A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
NCT01970904	Not specified	COMPLETED	Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).